Biotoxtech KRX:086040KOSDAQ
바이오톡스텍 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days2
DART filings, 7 days0
Articles tracked2since Sep 11
In Q2 2026, Biotoxtech reported revenue of ₩14.5bn, up 50.3% year on year, and an operating loss of ₩182m. Biotoxtech (바이오톡스텍) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 30 with 2 articles. The most common catalyst was contracts & orders (2).
Filing signals Insider buying Major holder adding 4 quarters of losses Screener
Biotoxtech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩14.5bn | +50.3% | −₩182m margin −1.3% | −₩6.9bn |
| Q1 2026 | ₩11.9bn | +5.5% | −₩1.8bn margin −15.4% | −₩2.7bn |
| Q4 2025 derived | ₩14.2bn | +24.7% | −₩98m margin −0.7% | −₩2.0bn |
| Q3 2025 | ₩11.9bn | +7.0% | −₩1.4bn margin −11.5% | ₩4.5bn |
| Q2 2025 | ₩9.6bn | -1.9% | −₩1.9bn margin −20.0% | −₩2.0bn |
| Q1 2025 | ₩11.2bn | +25.1% | −₩1.4bn margin −12.6% | −₩2.1bn |
| Q4 2024 derived | ₩11.4bn | +34.0% | −₩1.4bn margin −12.3% | −₩4.0bn |
| Q3 2024 | ₩11.1bn | +55.5% | −₩2.0bn margin −18.3% | −₩2.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Biotoxtech top stories 2 weeks, by number of outlets
- 1
- 2